The diagram provides a big picture view of the structure of CP2H and its anticipated flow of operations. At the top of the image, four categories of partners are identified: academia, industry, non-profit and government. They are supported by five pillars called platforms: platform 1 for virus vectors, vaccines and biotherapeutic innovations; platform 2 for small molecules, antimicrobials and antiviral therapeutics; platform 3 for scalable biomanufacturing innovations; platform 4 for diagnostics and clinical assays; and platform 5 for cross-cutting social sciences strategies.
At the bottom, five components are shown: the Ottawa Hospital’s Biotherapeutics Manufacturing Centre, McMaster University’s Robert E. Fitzhenry Vector Laboratory, uSaskatchewan’s Vaccine and Infectious Disease Organization (VIDO), uAlberta’s Alberta Cell Therapy Manufacturing (ACTM) and Dalhousie University’s Canadian Centre for Vaccinology (CCfV).
Those pillars are surrounded by arrows demonstrating the full operating cycle, starting at the top with health research, biomanufacturing and training, followed by new vaccines diagnostics and therapeutics, new startup companies, and clinical testing and commercial approval.